Pharmacologic SARM1 blockade to prevent Wallerian degeneration after axotomy
🧪 Overview
SARM1 is the executioner of axonal degeneration through its NMN hydrolase activity, and pharmacologic inhibition completely blocks Wallerian degeneration in acute injury models. Tool compounds (D-77, NVG-298) demonstrate in vivo efficacy in CIPN models, and Disarm Therapeutics has a Phase 1 program. The primary translational challenge is that ALS involves chronic multi-system failure rather than acute axotomy; SOD1 mouse models show only modest benefits from SARM1 deletion. Pursuing CIPN as an initial indication de-risks before ALS expansion.
🧬 Mechanism
⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — SARM1
No curated PDB or AlphaFold mapping for SARM1 yet. Search RCSB →
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for SARM1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
No resource usage or linked notebooks recorded for this hypothesis yet.
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |